ArticleCell communication and signaling : CCS2025
Polydatin upregulates ZDHHC19 to promote apoptosis of acute myeloid leukemia cells via mediating BID palmitoylation.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPolydatin, extracted from Polygonum cuspidatum, has been demonstrated to exert anti-tumor effects and induce apoptosis in several cancers including acute myeloid leukemia (AML). This study explored the potential mechanism of polydatin regulating apoptosis in AML. However, its precise molecular mechanism in AML remains poorly understood.
methodsPatients with AML or non-malignant hematological disease were recruited for collecting bone marrow samples. In AML cell lines, cell viability and apoptosis were determined with CCK-8 and flow cytometry, respectively. The palmitoylation level of BH3 interacting-domain death agonist (BID) was assessed using Acyl-RAC assay. The interaction between BID and zinc finger DHHC-type palmitoyltransferase 19 (ZDHHC19) was validated by co-immunoprecipitation. Western blot and immunofluorescence were used for measuring protein expression and localization. The role of polydatin in vivo was confirmed by establishing a xenograft model with nude mice, while Ki67 expression and apoptosis in tumors were measured with immunohistochemistry and TUNEL assay.
resultsZDHHC19 and BID palmitoylation were decreased in AML patients and cell lines. In HL-60 and MOLM-13 cells, polydatin treatment reduced cell viability, promoted apoptosis, and increased apoptosis-related proteins including BID, caspase-8, and cytochrome C. BID-cysteine (C)3/15-WT, but not BID-C3/15-Mut, led to increased BID palmitoylation and mitochondrial translocation. Polydatin treatment facilitated BID palmitoylation and apoptosis, when overexpressing BID-C3/15-WT but not BID-C3/15-Mut. The combination and co-localization of ZDHHC19 and BID were confirmed in AML cells. The effects of polydatin on promoting apoptosis and inhibiting tumor growth in vitro and in vivo were antagonized when silencing ZDHHC19.
conclusionThis study reveals a novel mechanism by which polydatin promotes apoptosis in AML through ZDHHC19-mediated BID palmitoylation. These findings suggest that polydatin may serve as a promising therapeutic candidate targeting apoptosis in AML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.